|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Similarly, currently available proprotein convertase subtilisin kexin type 9 inhibitors-alirocumab and evolocumab-both reduce ASCVD risk in statin-treated patients with diabetes.
|
31521544 |
2020 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Of 41 patients eligible for PCSK9 inhibitors, median age was 82 years (range 53-96); median vascular risk factors were 2 (range 1-5); 7 (17%) had TIA; 13 (31%) had history of preceding cerebrovascular events, 13 (31%) diabetes mellitus, 17 (42%) cardioembolic events, 9 (22%) lacunar syndrome, 11 (22%) symptomatic internal carotid artery stenosis (n = 9 were >70%), and 4 (10%) undetermined aetiology.
|
31732461 |
2020 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
PCSK9-targeted siRNA-driven strategies may provide a novel therapeutic option for managing dyslipidemia in the presence and absence of diabetes.
|
30487231 |
2019 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
350 patients (62 ± 11 years old, 58% men, 22% with diabetes mellitus) with different concomitant lipid lowering therapies, and in whom PCSK9-I treatment was indicated, received either evolocumab (140 mg) or alirocumab (75 or 150 mg).
|
30910670 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
We aimed to explore this issue in a prespecified analysis of the ODYSSEY OUTCOMES trial of the PCSK9 inhibitor alirocumab, assessing its effects on cardiovascular outcomes by baseline glycaemic status, while also assessing its effects on glycaemic measures including risk of new-onset diabetes.
|
31272931 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Although genetic variants associated with lower levels of LDL-C are also associated with an increased NOD risk, clinical trials with lipid-lowering drugs other than statins, namely ezetimibe or monoclonal antibodies against PCSK9, did not observe an increase of developing diabetes.
|
31029825 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
This article reviews the underlying aetiology and pathophysiology of this dyslipidaemia and atherosclerosis in those with diabetes, provides insights from epidemiological and genetic studies, and current cardiovascular risk reducing interventions including novel therapies such as PCSK-9 inhibitors.
|
31002453 |
2019 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Interestingly, compared with ezetimibe, which was actively used as lipid-modifying therapy in the control group, PCSK9-mAbs seem to have a lower risk of incident diabetes (RR 0.60, 95% CI 0.37-0.99; p = 0.04).
|
31823301 |
2019 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In patients with stable CAD, low PCSK9 plasma levels are associated with a particular metabolic phenotype (low HDL cholesterol, the metabolic syndrome, obesity, insulin resistance and diabetes) and diffuse non-obstructive coronary atherosclerosis.
|
31672148 |
2019 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Use of these PCSK9 inhibitors was not associated with increased risk of neurocognitive adverse events (P = 0.91), liver enzymes elevations (P = 0.34), rhabdomyolysis (P = 0.58), or new-onset diabetes mellitus (P = 0.97).
|
31270529 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
In studies reporting data on MACE and mortality separately for individuals with and without diabetes, the effect of PCSK-9 did not appear to be affected by diabetes.
|
30485622 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Further, state-of-the-art approaches, such as antibodies to PCKSK9 (proprotein convertase subtilisin-kexin type 9); RNA therapeutics; agents targeting distinct components of the immune/inflammatory response; and novel small molecules that block the actions of RAGE (receptor for advanced glycation end products) signaling, also hold potential as new therapies for diabetes mellitus and cardiovascular disease.
|
30786741 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Very recent treatment strategies include the PCSK9 inhibitors for hypercholesterolaemia and the SGLT2 inhibitors for reduction of cardiovascular events in patients with diabetes mellitus and increased cardiovascular risk.
|
30338502 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Statins remain first-line therapy in patients with diabetes, though newer therapies to reduce LDL-C have emerged, including ezetimibe as an add-on therapy to statins, and injectable PCSK9 inhibitors, both of which are safe and effective in diabetes.
|
31758270 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The safety of very low LDL-C concentrations and the link between LDL-C lowering and diabetes is also discussed.<b>Expert opinion</b>: PCSK9 monoclonal antibodies when added to background statin therapy, lowers LDL-C to previously unattainable levels.
|
31623472 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Like mutations with loss of function in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene, inhibitors of PCSK9 (PCSK9i) may potentially favor the manifestation of diabetes.
|
29180351 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis.
|
29377473 |
2018 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This post-hoc analysis evaluated efficacy and safety of the PCSK9 inhibitor alirocumab among 984 individuals with DM and ASCVD pooled from 9 ODYSSEY Phase 3 trials.
|
29802688 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
To evaluate the safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab according to diabetes mellitus status.
|
30183102 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the clinical trials of ezetimibe and PCSK9 inhibitors have not shown an increased DM risk, possibly suggesting that other potential non-well-defined "off-target effects" of hypolipidemic drugs may affect carbohydrate homeostasis.
|
29409336 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite strong indications from genetic studies that PCSK9 inhibition should increase diabetes risk, no such effect has been observed in clinical trials, and in-vitro and in-vivo studies do not clarify this issue.
|
30199407 |
2018 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A lifetime Markov Model was designed to estimate healthcare costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) for PCSK9 inhibition added to standard therapy in patients with Familial Hypercholesterolemia (FH), patients with vascular disease at high MACE recurrence risk, and patients with vascular disease with diabetes mellitus.
|
29306457 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The standardized prevalence rates of DM in FHBL1 were similar to those of the reference population, with a prevalence rate of 8.2 and 9.2%, respectively, while FHBL2 showed a 4.9% prevalence of DM.
|
27804036 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we assess the available evidence for the association of PCSK9 status with the incidence and control of DM in preclinical and clinical studies, and identify molecular mechanisms regulating PCSK9 expression in the diabetic state.
|
28111330 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
PCSK9 inhibition with evolocumab significantly reduced cardiovascular risk in patients with and without diabetes.
|
28927706 |
2017 |